Background
sepsis and infection are among the leading causes of death world-wide. The annual burden of sepsis in high income countries is rising with mortality of 40%. Despite these figures from industrialized countries, the largest part of the global sepsis burden occurs in middle and low- income countries, 90% of the world wide deaths from pneumonia, meningitis or other infections occur in less developed countries.
Aim of the Work
to evaluate the therapeutic efficiency of pentoxifylline as an adjuvant therapy in treatment of severe sepsis and its effect in multiple organ dysfunction and mortality in septic patients.
Materials and Methods
this is a randomized double blinded prospective study conducted from January 2015 to March 2016 included total sample size 52 cases (we used organ dysfunction as a primary outcome with proposed large effect size (0.8) and alfa=0.05 and power=0.80, so, 26 cases were needed in each group).
Results
we included 52 patients with sepsis who were divided in 1: 1 ratio to receive pentoxifylline or not. The average age of the included patients was almost 53 years, with no statistically significant different between both groups (p = 0.902); while the majority of the included patients were males, with no significant difference between both groups (p = 0.99). The mean weight was similar between both groups (84.50 ±11.25 vs. 83.65 ±10.54 years; p = 0.78) and chest disorders were the main cause of sepsis in both groups.
Conclusion
we concluded that PTX as an adjuvant therapy had no significant influence on the SOFA score, lactate level, CRP level, and pro-calcitonin level compared to control. Moreover, there were no statistically significant differences in terms of length of hospital stay, need for HD, need for vasopressor and inotropic, need for MV, and mortality rate. Further large clinical trials are recommended to assess the effectiveness of PTX especially with regards to organ failure, survival, and dose dependency.
A lot of researchers did their best to accelerate the cryptographic algorithms and develop high performance cryptographic schemes by using approaches such as the use of high end Grid computing. Grid computing is one of the most powerful techniques that can achieve a high acceleration for cryptographic algorithms. This approach makes the digital signature attractive for adoption by businesses to secure their documents. In this paper we propose and develop an application for digital signature cryptography using enterprise grid middleware called Alchemi. The modifying of the digital signature schema through compute hash in Alchemi parallel execution at two phases sign and verify said. The analyses of its performance are presented in two sides' sender and receiver by GridSign and GridVerify phases.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.